05.01.24
Pfizer
1Q Revenues: $14.9 billion (-20%)
1Q Earnings: $3.1 billion (-44%)
Comments: Global biopharmaceutical sales were $14.6 billion in the quarter, down 20%. Decline in Comirnaty and Paxlovid revenues drove 19% operational decrease in revenues. Comirnaty sales were $354 million, down 88% and Paxlovid sales were $2.0 billion down 50%. Global revenues from legacy Seagen, which was acquired in December of 2023, were $742 million. Vyndaqel family sales were $1.1 billion, up 66%. Eliquis sales were $2.0 billion in the quarter, up 9%. Prevnar sales were $1.7 billion, up 7%. Ibrance sales were down 8% to $1.05 billion. Oncology biosimilars sales were down 36%, largely due to lower net price in the U.S. Sulperazon internationally, was down 45% operationally, driven largely by lower demand in China.
1Q Revenues: $14.9 billion (-20%)
1Q Earnings: $3.1 billion (-44%)
Comments: Global biopharmaceutical sales were $14.6 billion in the quarter, down 20%. Decline in Comirnaty and Paxlovid revenues drove 19% operational decrease in revenues. Comirnaty sales were $354 million, down 88% and Paxlovid sales were $2.0 billion down 50%. Global revenues from legacy Seagen, which was acquired in December of 2023, were $742 million. Vyndaqel family sales were $1.1 billion, up 66%. Eliquis sales were $2.0 billion in the quarter, up 9%. Prevnar sales were $1.7 billion, up 7%. Ibrance sales were down 8% to $1.05 billion. Oncology biosimilars sales were down 36%, largely due to lower net price in the U.S. Sulperazon internationally, was down 45% operationally, driven largely by lower demand in China.